The long-term trend of the EPS is an important number as it indicates the present value of Osiris Therapeutics. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 8.30 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for Osiris Therapeutics since it indicates how well the business is allocating resources to benefit shareholders.
Osiris Therapeutics is part of the healthcare sector and is in the biotechnology industry. The company CEO is Jason Keefer. Osiris Therapeutics Inc is a biotechnology company. It is engaged in researching, developing and marketing cellular regenerative medicine products.
Previous Intraday Performance:
The OSIR shares had a previous change of -3.41% which opened at 10.35 and closed at 9.91. It moved to an intraday high of 10.39 and a low of 9.91.
SeekingAlpha: Nuverra Environmental acquires Clearwater
Over the last five trading days, OSIR shares returned -7.38% and in the past 30 trading days it returned 1.43%. Over three months, it changed -2.46%. In one year it has changed 117.80% and within that year its 52-week high was 13.70 and its 52-week low was 4.20. OSIR stock is 135.95% above its 52 Week Low.
Our calculations result in a 200 day moving average of 8.75 and a 50 day moving average of 10.11. Right now, OSIR stock is trading 13.22% above its 200 day moving average.
The company has a market cap of $342.2m with 34.5m shares outstanding and a float of 23.6m shares. Trading volume was 36,920 shares and has experienced an average volume of 81,471 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Osiris Therapeutics was 0.25 which ended on 31st of December 2017, which according to the previous close, that is a PE of 39.64.
Below was the last reported quarterly earnings per share:
Base on our calculations, the intrinsic value per share is 4.35, which means it might overvalued by -128.05%
Indicators Also to Watch:
Based on the latest filings, there is 31.70% of insider ownership and 6.10% of institutional ownership. Short-interest was 458,702, which was 1.33% of shares outstanding. The short-interest ratio or days-to-cover ratio was 4.91. This stock has some short interest, but it might be normal and no need to worry if long the position.
I calculated the beta to be 1.15
Based on last reported financials, the company’s return on equity is 23.58%, return on assets is 12.31%, profit margin is 7.68%, price-to-sales is 2.77 and price-to-book is 8.50.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result